Drug expansion: Pfizer ramps up obesity treatments with $4.9B Metsera deal; shares jump sharply
Pfizer is intensifying its entry into obesity treatments by acquiring development-stage drugmaker Metsera for $4.9 billion, the company announced Monday. The deal values each Metsera share at $47.50 in cash, a premium of more than 42% over Friday’s closing price, according to news agency AP report.Additional payments of $22.50 per share could be triggered depending…